Pioneering Code of Practice released for use of stem cell-based embryo models in research

• The University of Cambridge, in partnership with the Progress Educational Trust, has led work to create the first ever UK guidelines for the generation and use of stem cell-based embryo models in research;
• These models can be created in the lab and mimic aspects of early human embryo development, which raises various ethical considerations;
• The use of stem cell-based embryo models is not regulated explicitly by existing UK law, which has created uncertainty for scientists and held back research;
• The new SCBEM Code of Practice proposes clear guidance and oversight processes, to bring greater transparency and openness to the research and reassurance to the public;
• Research using embryo models can advance understanding of early human development and possible causes of infertility.

Stem cell-based embryo models (SCBEMs) are three-dimensional biological structures that mimic aspects of early human embryo development. They can be created in the lab from stem cells, and can provide new insights into critical stages of early human development that are normally inaccessible to researchers. Embryo model work is expected to lead to new interventions for a range of conditions, including revolutionising treatments for recurrent miscarriage, understanding developmental disorders and improving the success rate of IVF.

Although embryo models are not the same as human embryos, they mimic aspects of early human development - and this has raised ethical concerns. The previous lack of a regulatory framework for the use of SCBEMs in research has left scientists and research organisations uncertain about the acceptable boundaries of their work, both legally and ethically, and unsupported in their decision-making. Signing up to the SCBEM Code of Practice will remove these obstacles.

The guidelines, released today, provide the first code of practice for the use of stem cell-based embryo models in the UK.

“The new Code of Practice provides processes for decision-making in research using stem cell-based embryo models so that scientists can proceed confidently, while maintaining public trust in this vital area of research,” said Kathy Niakan, Director of the Centre for Trophoblast Research, and member of the SCBEM Code of Practice Working Group.

“Not only does the Code allow us to move forward with our research with renewed stability and confidence, it also brings greater transparency and openness in research using stem cell-based embryo models, helping to foster essential communication and understanding between scientists and society,” said Dr Peter Rugg-Gunn, CTR Group Leader, Head of Public Engagement at the Babraham Institute Member of the SCBEM Code of Practice Working Group.

Creation of the SCBEM Code of Practice (fully titled: Code of Practice for the Generation and Use of Human Stem Cell-Based Embryo Models) was led by Cambridge Reproduction - an interdisciplinary research centre at the University of Cambridge - in partnership with the Progress Educational Trust (PET) - a charity that improves choices for people affected by infertility and genetic conditions.

The SCBEM Code of Practice Working Group included researchers and practitioners from the Babraham Institute, Biolawgy, Brighton and Sussex Medical School, the Francis Crick Institute, Hull York Medical School, the Medical Research Council, Newcastle University, University College London, the University of Cambridge, the University of Edinburgh, the University of Exeter and the University of Manchester.

The work was funded by the BBSRC, the University of Cambridge Impact and Knowledge Exchange fund, and UKRI Sciencewise.

Download the Code of Practice

Adapted from a press release by the University of Cambridge: https://www.cam.ac.uk/stories/Code-of-Practice-Embryo-Models

Image: Human stem cell-based embryo model – Blastoids. Blue marks all nuclei, the green label marks cells of the inner cell mass, and the pink label is a readout of a ribosomal protein. Credit Irene Zorzan and Teresa Rayon, Babraham Institute.

BAP1/ASXL complex modulation regulates Epithelial-Mesenchymal Transition during trophoblast differentiation and invasion

VicentePerez-Garcia, PabloLopez-Jimenez, Graham JBurton, AshleyMoffett, Margherita YTurco, MyriamHemberger

Each year, the Hans Sigrist Foundation at the University of Bern in Switzerland puts out a call to all the professors at its eight faculties to submit proposals for a field for the coming year’s Hans Sigrist Prize.  The prize is not a lifetime achievement award, but instead, it recognizes a top mid-career academic researcher/scientist working in the prize field, who has already done ground-breaking research and who shows promise for more.  It is funded by a bequest left by a wealthy benefactor who studied at the University of Bern.

Prof. Norbert Trautmann, President of the Hans Sigrist Foundation, explains, “What sets the Hans Sigrist Prize apart from many others is that the field changes from year to year.  When the foundation was established, the board wanted to be able to recognize exceptional research in all academic fields.  Due to the interdisciplinary nature of the board, it has allowed us also to recognize research that may have impacts and applications for more than one discipline, for example, this year’s prize committee included experts from the University of Bern’s medical, veterinary, and natural sciences (biology) faculties.”

Prof. Christiane Albrecht is a member of the medical faculty at the University of Bern, whose research focuses on the molecular regulation of maternal-fetal transport processes across the placenta and, related to this, mechanisms of maternal-fetal communication.  She proposed this year’s prize field “Maternal-fetal Communication during Pregnancy” and served as the prize committee chair.  Prof. Albrecht reflects, “As soon as the foundation approved the prize field, I put together a committee of experts, and we began to review the work of cutting-edge academics working in the prize field worldwide.  It is an area where a great deal of exciting work is being done, so the process was highly competitive and difficult.  Ultimately, after considering the candidates and their work and reviewing outside reviewers’ reports, the 2020 prize committee nominated Dr. Amanda Sferruzzi-Perri of the University of Cambridge to the foundation board as our top choice. The board then decided to award her with the 2020 Hans Sigrist Prize.”

Dr. Sferruzzi-Perri’s research is dedicated to unravelling the epigenetic and genetic regulation of the placenta and, closely related to this, the in utero programming of adult diseases.  With her studies showing the influence of the mother’s environment, the placenta in controlling maternal-fetal resource allocation, and her original seminal work on insulin/IGE signaling and fetal growth disorders,  Dr. Sferruzzi-Perri has elucidated fundamental concepts of maternal-fetal communication and the fetal origins of health and adult diseases.  Her innovative work has motivated further scientific study on the placenta and the design of strategies to prevent pregnancy complications and to improve the life-long health of mothers and their offspring.   

Dr. Sferruzzi-Perri, as the 2020 Hans Sigrist Prize Winner, will receive 100,000 Swiss francs to dedicate to her research, as well as being recognized at the University of Bern’s Dies Academicus (a formal annual academic ceremony) and at the annual Hans Sigrist Symposium at the University of Bern, where she and other experts from the field will speak about Maternal-fetal Communication.  Due to the pandemic, the Hans-Sigrist Symposium will take place in 2021, rather than in December 2020.

More information about the Hans Sigrist Foundation and the prize, are available on the Hans Sigrist Foundation website.    An interview with Dr. Sferruzzi-Perri will also soon be published on the website. 

Key points of the Code

The new SCBEM Code of Practice sets out standards to make sure that research using SCBEMs is rigorous, upholds ethical principles and maximises the potential benefits. Key to this will be a dedicated Oversight Committee that will review each proposed research project.

The Code recognises that there must be a limit to how long embryo models can be grown in the lab. However, many different types of embryo model are being developed, representing distinct developmental stages and developing at different rates, making it impossible to impose a single fixed limit. Instead, researchers will be required to provide clear justification of the length of their experiments on a case-by-case basis.

The Code prohibits any human SCBEM from being transferred into the womb of a human or animal, or being allowed to develop into a viable organism in the lab.

“Embryo models have huge potential and we want to realise this, while also limiting the risks. The new Code of Practice will allow stem cell-based embryo models to be grown in the lab long enough to gain meaningful biological understanding, but researchers will have to fully justify what they’re doing in scientific and ethical terms,” said Niakan.

How are embryo models useful to research?

Research using embryo models can improve knowledge of human development, including early pregnancy loss and pregnancy disorders, congenital defects and the precursor events that affect adult human health and disease.

The models could also be used for some investigations that are not permitted using human embryos. For example, there are currently significant limitations to clinical trials and the use of many medicines during pregnancy. Models of early development could be helpful to improve options for drug treatments during pregnancy in the future.

Stem cell-based embryo models open new research avenues that can complement, but not replace, the limited studies possible with actual human embryos. The SCBEM Code of Practice states that neither of these areas of research can or should replace the other for the foreseeable future.

How was the Code produced?

The SCBEM Code of Practice Working Group was made up of researchers and practitioners at institutions across the UK, including experts in science, law, ethics and regulation. In drawing up the Code, the team consulted widely with researchers, practitioners, and major funders and regulators of embryo model research.

The work was also informed by a public dialogue, held earlier this year, to explore public attitudes towards research involving embryo models.

“Throughout the process of developing the Code of Practice, we’ve been keen to engage with as wide a range of stakeholders as possible, including researchers, experts in law and bioethics, regulators and funders,” said Christina Rozeik,Programme Manager of Cambridge Reproduction and member of the SCBEM Code of Practice Project Team. She added: “A public dialogue enabled us to include public voices during the development of the Code, taking account of their hopes, concerns and sensitivities around research involving stem cell-based embryo models. Participants were excited by the potential of embryo model research, but also strongly supportive of oversight.”

“Research involving stem cell-based embryo models has enormous potential to improve human knowledge and health, but clearer governance is needed to help researchers work responsibly and maintain public trust. Our Code of Practice addresses this need. It takes into account an extensive range of expert and lay perspectives we’ve gathered over the past year,” said Sandy Starr, Deputy Director of the Progress Educational Trust (PET) and member of the SCBEM Code of Practice Project Team.

How will the Code be enforced?

The Code is not legislative, but the teamproposes that it should be adopted by UK researchers, funders, research organisations, professional societies and publishers.

Widespread use is expected to deter the funding and publication of research that fails to meet the standards set out in the Code. As a result, adherence to the Code will become an essential part of credible science, providing increased transparency and accountability for embryo model research.

Given the rapid pace of research using embryo models, the Code will be reviewed regularly.

“Research using stem cell-based embryo models is very new, and our understanding of the science is rapidly evolving. We’ve taken the opportunity to respond to the current situation, and we’ll continue to update the Code of Practice as the science continues to develop,” said Niakan.

“Establishing this guidance takes stem cell-based embryo models out of the grey zone and onto more stable footing so we can fully explore their usefulness, while providing the essential reassurance that this research is being conducted carefully and with appropriate scrutiny,” said Dr Peter Rugg-Gunn, Group Leader and Head of Public Engagement at the Babraham Institute, and member of the SCBEM Code of Practice Working Group.